ARCT Stock Analysis: Buy, Sell, or Hold?
ARCT - Arcturus Therapeutics Holdings Inc. Common Stock
$8.03
0.18 (2.29%)
▲
5d:
+13.42%
30d:
+5.94%
90d:
+31.0%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Distribution
ARCT is up 11.0% this week, but smart money is buying puts. Top strike: $7.5 2026-06-18 with 837 OI. Put ratio: 62% View Scanner →
Strength: 6.8/10
Get Alerted When ARCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ARCT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ARCT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ARCT is currently trading at $8.03, which is considered extended relative to its 30-day fair value range of $6.73 to $7.95.
Technical Outlook: Technically, ARCT is showing sideways momentum. The price is approaching resistance at $8.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ARCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $23.30 (+190.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARCT is showing sideways momentum. The price is approaching resistance at $8.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ARCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $23.30 (+190.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$6.73 -
$7.95
Company Quality Score
55/100
(HOLD)
Options IV Signal
30th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 30th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 190.2% below Wall St target ($23.30)
Fair Price Analysis
30-Day Fair Range
$6.73 -
$7.95
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$1.33
(16.6%)
Support & Resistance Levels
Support Level
$6.54
Resistance Level
$8.27
Current Trend
Sideways
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.91
Wall Street Target
$23.30
(+190.2%)
Revenue Growth (YoY)
-68.4%
Profit Margin
-80.2%
Share & Embed Analysis
Last updated: April 02, 2026 5:08 PM ET
Data refreshes hourly during market hours. Next update: 6:08 PM
Data refreshes hourly during market hours. Next update: 6:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
